Finance

Lists
Why is ZURA down 2.30%?
Dive Deeper
ZURA:NASDAQ
Zura Bio Ltd
$0.93
-2.30%
(-0.022) 1D
$0.93
-0.04% (-0.00040)
After hours
Closed: Nov 20, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZURA...
Open
$0.94
High
$1.00
Low
$0.92
Mkt. cap
89.86M
Avg. vol.
7.10M
Volume
4.77M
52-wk high
$7.44
52-wk low
$0.92
EPS
-$1.11
Beta
0.03
Shares outstanding
96.32M
No. of employees
40
Open
$0.94
High
$1.00
Low
$0.92
Mkt. cap
89.86M
Avg. vol.
7.10M
Volume
4.77M
52-wk high
$7.44
52-wk low
$0.92
EPS
-$1.11
Beta
0.03
Shares outstanding
96.32M
No. of employees
40
News stories
From web sources and news partners
About Zura Bio Ltd
CEO-
Employees40
Founded2022
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to ZURA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ZURA in the last 3 months.
Highest
Current $0.93
$26.00 (+2,694.20%)
Average
$10.67 (+1,046.70%)
Lowest
$5.00 (+437.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kaveri Pohlman
Clear Street
Buy
Maintained
$10.00
+974.7%
11/10/2026
Justin Kim
Oppenheimer
Buy
Maintained
$5.00
+437.3%
11/10/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$8.00
+759.8%
11/10/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$5.00
+437.3%
11/09/2026
Martin Fan
Wedbush
Buy
Reiterated
$10.00
+974.7%
11/09/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$26.00
+2,694.2%
10/07/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$11.00
+1,082.2%
10/02/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$20.00
+2,049.4%
10/02/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/11/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$11.00
+1,082.2%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.96M
14.75M
20.71M
19.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.46M
10.75M
8.62M
9.28M
Operating expense
18.41M
25.50M
29.32M
28.77M
Total operating expenses
18.41M
25.50M
29.32M
28.77M
Operating income
-18.41M
-25.50M
-29.32M
-28.77M
Other non operating income
-40.00K
-43.00K
1.02M
-32.00K
EBT including unusual items
-17.18M
-24.22M
-26.38M
-27.05M
EBT excluding unusual items
-17.18M
-24.22M
-26.38M
-27.05M
Income tax expense
-
-
-81.00K
-1.22M
Effective tax rate
-
-
0.31%
4.51%
Other operating expenses
-
-
-
-
Net income
-17.18M
-24.22M
-26.30M
-25.82M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.22
-0.21
-0.20
Interest and investment income
1.28M
1.32M
1.92M
1.76M
Interest expense
-
-
-
-
Net interest expenses
1.28M
1.32M
1.92M
1.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.40M
-25.48M
-29.30M
-28.75M
Gain or loss from assets sale
-
3.00K
2.00K
1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps